umikibart (YYB-101) / National OncoVenture, CellabMed - LARVOL DELTA

A phase Ib/IIa study to assess the safety, tolerability, pharmacokinetics, and antitumor activity of YYB101, hepatocyte growth factor neutralizing humanized monoclonal antibody, in combination with irinotecan in metastatic or recurrent colorectal cancer patients (NOV110501-201) (ESMO 2023) - P1b/2a | "Conclusions The YYB101 and irinotecan combination showed modest efficacy and tolerable adverse events in refractory metastatic/recurrent CRC. Ongoing biomarker analyses aim to identify genomic and transcriptomic variables associated with long-term disease control."

Clinical • Combination therapy • Metastases • P1/2 data • PK/PD data • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor • HGF

To Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of YYB101 With Irinotecan, Patients Who Are Metastatic or Recurrent Colorectal Cancer Patients (clinicaltrials.gov) - P1b/2a | N=35 | Completed | Sponsor: CellabMED | Unknown status ➔ Completed | Trial completion date: May 2021 ➔ Dec 2021 | Trial primary completion date: Jun 2020 ➔ Dec 2021

Combination therapy • Trial completion • Trial completion date • Trial primary completion date • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor

A Novel CAR-T Cell Therapy Strategy to Inhibit Hepatocyte Growth Factor in Solid Tumor (ASGCT 2022) - " To examined efficacy of YYB-103 CAR-T and/or anti-HGF monoclonal antibody, in vivo experiment was performed in orthotopic xenograft mouse model using HGF-overexpressing ovarian cancer cell line A2780/IL13Rα2. Our experimental results showed that inhibition of HGF could be one strategy to improve the efficacy of CAR-T in solid tumors. Further study is ongoing to confirm experimental evidences that our new type of CAR-T, YYB-101 scFv-releasing CAR-T, actually acts on the immunosuppressive tumor microenvironment of solid tumors."

CAR T-Cell Therapy • Brain Cancer • Glioblastoma • Hematological Disorders • Hematological Malignancies • Oncology • Ovarian Cancer • Solid Tumor • CD8 • IFNG • IL13RA2 • MET

Celllab Med completes 23.3 billion Series B funding [Google Translation] (thebell) - “Accelerate clinical trials for colorectal cancer treatment, focus on expanding GMP-grade manufacturing facilities. Celllab Med has completed a series B investment worth 23.3 billion won. CelllabMed plans to use the funds raised for the expansion of indications for the antibody treatment CLM-101 (existing YYB-101), which is its core pipeline, and biomarker discovery. Celllab Med attracted 10 domestic institutional investors in this Series B round. Existing investment institutions, Kolon Investment and Wooshin Venture Investment, made follow-up investments (follow-on). K2 Investment, NH Investment & Securities, TS Investment, Aion Asset Management, Tigris Investment, Fine Value Asset Management, Korea Investment & Securities, and Hanwha Investment & Securities participated as new investors. It succeeded in attracting additional investment two years after it raised 10.5 billion won in Series A investment in 2019. The total amount of investment that the company has...

Grant • Colorectal Cancer • Oncology

Safety and Pharmacokinetics Study of YYB101 in Advanced Solid Tumors Patients Who Are Refractory to Standard Therapy (clinicaltrials.gov) - P1; N=39; Completed; Sponsor: CellabMED; Recruiting ➔ Completed

Clinical • Trial completion • Oncology • Solid Tumor

YYB-101, a Humanized Antihepatocyte Growth Factor Monoclonal Antibody, Inhibits Ovarian Cancer Cell Motility and Proliferation. (PubMed, Anticancer Res) - "YYB-101 can be examined as a new therapeutic agent for the treatment of patients with ovarian cancer."

Journal • Oncology • Ovarian Cancer • Solid Tumor • PXN

First-in-human phase I trial of anti-hepatocyte growth factor antibody (YYB101) in refractory solid tumor patients. (PubMed, Ther Adv Med Oncol) - P1 | "Based on this phase I trial, a phase II study on the YYB101 + irinotecan combination in refractory metastatic colorectal cancer patients is planned. ClinicalTrials.gov Identifier: NCT02499224."

Clinical • IO Biomarker • Journal • P1 data • Colorectal Cancer • Fatigue • Gastrointestinal Cancer • Hematological Disorders • Oncology • Solid Tumor • HGF • MAPK1 • PD-L1